EURO GP FORMULARY NEXT YEAR?

17 May 1992

An informal group of experts from European Community countries is planning to publish the first EC-wide drug formulary for general practitioners next year with, it hopes, support from the EC Commission and the World Health Organization.

Drug use throughout the EC differs widely, according to the group, which adds that many countries appear not to have GP formularies.

The purpose of the formulary will be to provide "simple, adequate and appropriate" treatments for conditions which present most commonly in general practice. It would include approximately 150 drugs, and its authors intend to exclude products which have been introduced within the past five years, unless they show clear major advantages over established treatments. The authors also plan to address through the formulary the issue of whether certain drugs are needed at all.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight